IOL Chemicals and Pharmaceuticals share news, announcements and annual reports

NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap

IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 · Listed Feb 1991 on BSE, Nov 2010 on NSE

₹177.65₹7.28 (3.94%)BSE ₹177.75

Share price at the NSE close on 30 Oct 2026. Previous close ₹184.93.

30 Oct: open ₹186.40, high ₹186.40, low ₹176.02

52-week range of traded prices to 30 Oct 2026

₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026

Market cap: ₹5,215 Cr1,024th largest listed
P/E: 25.66
P/B: 2.71
Dividend yield: 0.56%
ROE: 11.1%
ROCE: 13.1%
Debt to equity: 0.10
Volume, NSE: 18,08,91234.0% delivered

IOL Chemicals and Pharmaceuticals share news and announcements

709 announcements, routine notices left out, newest first. Page 11 of 15.

Feb 2018
- 12 Feb · Business
  Press release dated February 12, 2018, titled "Press Release for Financial Results and successfully completed unit IV to manufacture Metformin, an anti- diabetic drug".
- 12 Feb · Board meeting
  Outcome of Board Meeting held on February 12, 2018.
- 12 Feb · Results
  Financial results for the period ended December 31, 2017.
- 3 Feb · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter and nine months ended December 31, 2017.
Nov 2017
- 13 Nov · Business
  Press release dated November 13, 2017, titled "Press Release for Financial Results and to invest ` 200 crores in expanding its existing manufacturing capacities including its flagship product, Ibuprofen ".
- 13 Nov · Board meeting
  Outcome of Board Meeting held on November 13, 2017.Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 13 November 2017 had approved the following:1. Un-audited Financial Results of the Company for the quarter and half year ended 30 September 2017.2. To enhance the manufacturing capacity of Ibuprofen from 7200 TPA to 12000 TPA and enhance the capacities of backward integrated products i.e. Iso butyl Benzene from 9000 TPA to 12000 TPA, MCA from 7200 TPA to 10500 TPA and Acetyl Chloride from 5200 TPA to 8400 TPA with a project cost of ` 200 crore which will be met through combination of equity, internal accruals and loans over a period of two years.3. Setting up Unit IV for manufacturing Metformin an anti diabetic drug with a capacity of 2880 MT per annum with project cost of ` 10 crore which will be financed through internal accruals.Further the Company has completed and commercialized Unit III to manufacture Fenofibrate, Clopidogrel and Lamotrigine etc. with project cost of ` 16.48 crore met through internal accruals. Please find enclosed herewith the following:1. Un-audited Financial Results for the quarter and half year ended 30 September 20172. Independent Auditors Review Report on the Un-audited Financial Results for the quarter and half year ended 30 September 2017.Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 04:50 p.m.
- 13 Nov · Results
  Financial results for the period ended September 30, 2017.
- 6 Nov · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter and half year ended September 30, 2017.
Oct 2017
- 24 Oct · Legal
  Significant increase in price has been observed in IOL Chemicals and Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. IOL Chemicals and Pharmaceuticals Limited has submitted their response.
  The exchange asked on 23 Oct 2017
Sep 2017
- 29 Sep · Meeting
  Copy Srutinizers report of Annual General Meeting held on September 28, 2017. Further, the company has informed the Exchange regarding voting results.
- 28 Sep · Meeting
  Proceedings of Annual General Meeting held on September 28, 2017
- 1 Sep · Meeting
  Register of Members & Share Transfer Books of the Company will remain closed from September 21, 2017 to September 21, 2017 (both days inclusive) for the purpose of Annual General Meeting.
- 1 Sep · Meeting
  Notice of Annual General Meeting to be held on September 28, 2017
Aug 2017
- 18 Aug · Business
  Press release dated August 18, 2017, titled "Impressive Results by IOL Chemicals and Pharmaceuticals Limited".
- 18 Aug · Board meeting
  Outcome of Board Meeting held on August 18, 2017.Dear Sir,Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in its meeting held on 18 August 2017 had approved the Un-audited Financial Results of the Company for the quarter ended 30 June 2017. Further the Board took note of increase in manufacturing capacity of the Ibuprofen from 6200 TPA to 7200 TPA by conversion of existing multipurpose plant.Please find enclosed herewith the following:1. Un-audited Financial Results for the quarter ended 30 June 20172. Independent Auditors Review Report on the Un-audited Financial Results for the Quarter ended 30 June 2017Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 05:00 p.m.
- 18 Aug · Results
  Financial results for the period ended June 30, 2017.
- 10 Aug · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter ended June 30, 2017.
May 2017
- 29 May · Results
  There was a printing error in that published extract of audited financial results wherein amount referred is wrongly printed as Rs in lacs in place of Rs in crore . Therefore all amounts in the published extract of audited financial results for the quarter / year ended March 31, 2017 be read as Rs in crore . Further the Company has submitted a copy of corrected extract of audited financial results for the quarter / year ended March 31, 2017 for information of the investors.
- 27 May · Board meeting
  Outcome of Board Meeting held on May 27, 2017.Dear Sir,Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you the Board of Directors in its meeting held on 27 May 2017 had approved the Following:1. Audited Financial Results for the Quarter/ Financial year ended 31 March 20172. Acceptance of Resignation of Mr Vijay Singla from directorship of the company with effect from 27 May 2017.Further we are enclosed herewith the following:1. Audited Financial Results for the Quarter/ Financial year ended 31 March 20172. Unmodified Independent Auditor s Report on Financial Results for the Quarter/ Financial year ended 31 March 20173. Declaration from the company regarding Independent Auditor s issuing of Audit Report with unmodified opinion on audited financial results. 4. Press Release for the results.Kindly note that the meeting of Board of Directors commenced at 12:00 noon and concluded at 3:30 p.m.This is for your information & record please.
- 27 May · Results
  Financial results for the period ended March 31, 2017.
- 20 May · Board meeting
  Inter-alia to consider and approve the audited financial results of the Company for the quarter and year ended 31 March 2017. Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall remain closed from 21 May 2017 and will open after 48 hours, the financial results for the quarter and the year ended 31 March 2017 made public.
Apr 2017
- 12 Apr · Updates
  Company has received EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary, for its product Ibuprofen, Lamotrigine, Metformin Hydrochloride confirming compliance with principals of Good Manufacturing Practices as provided by European Union Legislation.
- 8 Apr · Disclosure
  Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Feb 2017
- 11 Feb · Board meeting
  Outcome of meeting of the Board of Directors of the Company held on February 11, 2017.
- 11 Feb · Results
  Financial results for the period ended December 31, 2016.
Jan 2017
- 31 Jan · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter and nine months ended December 31, 2016.
- 4 Jan · Rating
  Credit Rating Pursuant to Regulation 30 and any other provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Credit Analysis & Research Ltd (CARE) has revised the credit rating for Long term Bank Facilities to CARE BB; Stable (Double B; Outlook: Stable) from 'CARE BB-' (Double B Minus) and reaffirmed the credit rating for Short term Bank Facilities to 'CARE A4' (A Four).
Dec 2016
- 15 Dec · Updates
  Company has won the National Energy Conservation Award - 2016. The company has awarded with the Second prize in Chemical Sector for its continued efforts towards new technology implementation so as to conserve energy resources of the country. Mr Vijay Singla, Director (Works) received the award from Sh. Pyush Goyal - The Hon'ble Minister of State (I/C) for Power, Coal, New & Renewable Energy and Mines at a National Energy Conservation Award function held on December 14, 2016, National Energy Conservation Day, at New Delhi.
Nov 2016
- 7 Nov · Results
  Financial results for the period ended September 30, 2016.
- 1 Nov · Analysts
  Analysis report ob the company by IIFL Wealth Management Limited.
Oct 2016
- 30 Oct · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter and half year ended 30 September 2016.
Sep 2016
- 29 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
  Details of voting results of the Annual General Meeting of the Company held on the September 28, 2016 along with Report of Scrutinizer.
- 28 Sep · Meeting
  Proceedings of the Annual General Meeting held on September 28, 2016.
- 1 Sep · Meeting
  Register of Members & Share Transfer Books of the Company will remain closed September 21, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on September 28, 2016.
- 1 Sep · Meeting
  Notice of Annual General Meeting of the members of the Company to be held on September 28, 2016.
Aug 2016
- 8 Aug · Board meeting
  Outcome of board meeting held on August 08, 2016 along with the Press release.
- 8 Aug · Business
  Vide letter dated August 08, 2016 regarding a press release , titled "Impressive Results by IOL Chemicals and Pharmaceuticals Limited".
- 8 Aug · Results
  Standalone financial results along with the Limited Review Report for the period ended June 30, 2016.
Jul 2016
- 30 Jul · Board meeting
  Inter-alia to consider and approve the un-audited financial results of the Company for the quarter ended June 30, 2016. Further, in terms of provisions of the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the "Trading Window" of the Company shall remain closed from July 31, 2016 and will open after 48 hours, the financial results for the quarter ended June 30, 2016 made public.
Jun 2016
- 14 Jun · Updates
  Company proposes to make applications to the Central Government for its approval under Section 197, Schedule V and other applicable provisions of the Companies Act, 2013 to the variation in term of appointment of Mr Varinder Gupta, Managing Director and Mr Vikas Gupta, Executive Director in respect of increase in their remuneration w.e.f. April 1, 2016 for remaining tenure.
May 2016
- 14 May · Board meeting
  Mr Yogesh Goel, Independent Director and Mr Ravi Pratap Singh, Independent Director, have tendered resignations from the directorship of the company which were accepted by the Board of Directors in its meeting held on May 14, 2016. The Board appreciated the services rendered by them during their tenure as directors of the company.
- 2 May · Business
  Press release dated May 02, 2016 titled "Impressive Results by IOL Chemicals and Pharmaceuticals Limited"
- 2 May · Results
  Standalone financial results along with the Auditors Report for the period ended March 31, 2016.
Apr 2016
- 25 Apr · Board meeting
  Inter-alia to consider and approve the audited financial results of the Company for the quarter and the financial year ended March 31, 2016.
- 12 Apr · Updates
  Company proposes to make a application to the Central Government for its approval under Section 196, 197, 203, Schedule V and other applicable provisions of the Companies Act, 2013 for re-appointment of Mr Vijay Kumar Garg as Joint Managing Director of the company.
- 11 Apr · Disclosure
  Vide letter dated April 06, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Mar 2016
- 29 Mar · Meeting Updates
  Independent Directors in their meeting held on March 29, 2016 inter-alia reviewed the performance of non-independent directors and the Board as a whole; reviewed the performance of the Chairman of the company and assessed the quality, quantity and timeliness of flow of information between the company management and the Board in line with the requirement of regulation 25 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 read with applicable provisions of Schedule IV of the Companies Act, 2013.
- 3 Mar · Updates
  Certificates of Pharmaceuticals Products (COPP) confirming WHO guidelines
- 3 Mar · Rating
  Credit Analysis & Research Ltd (CARE) has reaffirmed the following credit rating for long term and short term bank facilities of the company:Long term Bank Facilities : 'CARE BB-' (Double B Minus)Short term Bank Facilities : 'CARE A4' (A Four).
Jan 2016
- 30 Jan · Board meeting
  Outcome of the Board Meeting held on January 30, 2016.

IOL Chemicals and Pharmaceuticals share news and announcements

Feb 2018

Nov 2017

Oct 2017

Sep 2017

Aug 2017

May 2017

Apr 2017

Feb 2017

Jan 2017

Dec 2016

Nov 2016

Oct 2016

Sep 2016

Aug 2016

Jul 2016

Jun 2016

May 2016

Apr 2016

Mar 2016

Jan 2016